Astrotech Corp (ASTC) 10-K Summary: Fiscal Year Ended June 30, 2024
Business Context and Reporting Period
This filing is an Annual Report on Form 10-K for Astrotech Corporation (Nasdaq: ASTC) for the fiscal year ended June 30, 2024. Astrotech commercializes the Astrotech Mass Spectrometer Technology (AMS Technology) platform through four wholly-owned subsidiaries targeting distinct markets:
- 1st Detect: Security and detection (Explosives/Narcotics Trace Detectors).
- AgLAB: Agriculture (Hemp/Cannabis distillation optimization).
- BreathTech: Medical diagnostics (Breath analysis for infections).
- Pro-Control: Industrial process control (Chemical distillation).
The company is classified as a non-accelerated filer and a smaller reporting company. As of June 30, 2024, the company employed 30 people.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2024 | Fiscal 2023 |
|---|---|---|
| Revenue | $1,664 | $750 |
| Cost of Revenue | $913 | $444 |
| Gross Profit | $751 | $306 |
| Gross Margin | 45.1% | 40.8% |
| Operating Expenses | $14,031 | $11,366 |
| Net Loss | $(11,666) | $(9,642) |
| Cash and Cash Equivalents | $10,442 | $14,208 |
| Short-term Investments | $21,474 | $27,919 |
| Accumulated Deficit | $(237,020) | $(225,354) |
Liquidity: Net working capital was approximately $32.2 million as of June 30, 2024. The company reported no long-term debt as of the reporting date, having repaid all related-party notes in prior periods.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 121.9% to $1.7 million, driven by higher unit sales of the TRACER 1000 and recurring maintenance/consumable revenue.
- Operating Expenses: Total operating expenses rose 23.4% to $14.0 million. Selling, General, and Administrative (SG&A) expenses increased 25.4% due to personnel costs and public company expenses. R&D expenses increased 21.4% to support cross-platform technology improvements.
- Cash Position: Cash and cash equivalents decreased by $3.8 million to $10.4 million, primarily due to funding operating expenses, partially offset by proceeds from short-term investments.
- Customer Concentration: Revenue remains highly concentrated. In 2024, three material customers comprised substantially all revenue, compared to four in 2023.
Guidance, Outlook, and Risks
Management Commentary & Milestones:
- TSA Approval: On June 20, 2024, the TRACER 1000 was approved by the U.S. Transportation Security Administration (TSA) for the Air Cargo Security Technology List (ACSTL), advancing to Stage II field trials.
- GSA Contract: The TRACER 1000 ETD and NTD were listed on the U.S. General Services Administration (GSA) IT Schedule 70 in April 2024, enabling sales to the federal government.
- AgLAB Partnership: Entered a master lease agreement with SC Laboratories in June 2024 for joint marketing of the AgLAB 1000-D2.
- BreathTech: Commercialization of the BreathTest-1000 is paused in favor of capital deployment to other units, though the Joint Development Agreement with Cleveland Clinic remains active.
Risks and Contingencies:
- Profitability: The company has an accumulated deficit of $237 million and anticipates continued losses. It may need to raise additional capital, potentially causing dilution.
- Regulatory Uncertainty: AgLAB's business is tied to the hemp/cannabis industry, which faces federal legal risks (Schedule I substance). BreathTech requires FDA clearance (510(k) or De Novo) which is uncertain and lengthy.
- Customer Concentration: Loss of one or two key customers could materially harm operations.
- Supply Chain: Reliance on single-source suppliers for critical components poses risks of production delays.
Investor Verification Checklist
- Verify the status of the TSA Stage II field trials for the TRACER 1000 and the timeline for "qualified" list status.
- Confirm the specific revenue contribution of the three material customers and the terms of their contracts (long-term vs. spot orders).
- Assess the runway of current cash ($10.4M) against the burn rate (~$11.7M annual net loss) to determine the need for near-term capital raises.
- Review the regulatory pathway and FDA communication status for the BreathTest-1000.
- Monitor the impact of federal cannabis enforcement policies on the AgLAB subsidiary's market access.